LLMs demonstrated high accuracy in matching brand and generic names (GPT-4o: 97.38% for brand, 94.71% for generic, P < .01). However, they showed significant inconsistencies in word association tasks.

There were 262,063.05 new cases, 2,742,285.75 prevalence, 115,973.98 deaths, and 2,260,975.34 DALYs of breast cancer among older adults in 2021 in Asia. From 1990 to 2021, the ASRs of breast cancer ...

Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status. Anti-PD1 antibodies ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Between February 2023 and July 2024, we enrolled 125 of 174 approached caregivers (71.8%). Participants assigned to the BMT-CARE App used the app for a median of 146.9 minutes (range, 0-384.8). At day ...

Background: Treatment options for pts with R/M SGC are limited. Responses to chemotherapy (CT) are low with high toxicity and responses to immune checkpoint inhibition (ICI) are <10%. Pemetrexed (PTX) ...

Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain ...

Creating value-aligned treatment pathways in breast cancer requires understanding the cost and cost-effectiveness of new therapies. To address uncertainty in the optimal treatment sequence, we ...

Approximately 6,600 new cases of ALL and 1,300 deaths related to ALL were reported in the United States in 2024. 1 The incidence of ALL decreases with age; 25% of patients are age 20-60 years, and 11% ...

Exacerbating these concerns, trial-related nonmedical costs may disproportionately affect lower socioeconomic status populations. A 2017 analysis of 1,600 cancer clinical trial participants found that ...

Recruitment for LCS programs faces numerous challenges, including socioeconomic, cultural, logistical, and racial disparities. Current LCS guidelines often fail to address differences in sex, smoking ...

Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...